Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors
/in Breast Cancer, Dendritic Cells, International Publications /von 2023-07-15 / J Immunol 2023 Jul;211(2):219-228Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy
/in Breast Cancer, Dendritic Cells, International Publications /von 2023-04-12 / Biomed Pharmacother 2023 Jun;162:114685Inhibition of Tumor Growth and Metastasis by Newcastle Disease Virus Strain P05 in a Breast Cancer Mouse Model
/in Breast Cancer, International Publications, Newcastle Disease Virus /von 2023-02-17 / J Breast Cancer 2023 Apr;26(2):186-200Immunotherapy in breast cancer: an overview of current strategies and perspectives
/in Breast Cancer, International Publications /von 2023-02-13 / NPJ Breast Cancer 2023 Feb;9(1):7Modification of Breast Cancer Milieu with Chemotherapy plus Dendritic Cell Vaccine: An Approach to Select Best Therapeutic Strategies
/in Breast Cancer, Dendritic Cells, International Publications /von 2023-01-17 / Biomedicines 2023 Jan;11(2)3-Dimensional coculture of breast cancer cell lines with adipose tissue-Derived stem cells reveals the efficiency of oncolytic Newcastle disease virus infection labeling technology
/in Breast Cancer, International Publications, Newcastle Disease Virus /von 2022-09-12 / Front Mol Biosci 2022;9:754100Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches
/in Breast Cancer, Dendritic Cells, International Publications /von 2022-08-03 / J Control Release 2022 Sep;349:844-875Glucose Deprivation Induced by Acarbose and Oncolytic Newcastle Disease Virus Promote Metabolic Oxidative Stress and Cell Death in a Breast Cancer Model
/in Breast Cancer, International Publications, Newcastle Disease Virus /von 2022-07-22 / Front Mol Biosci 2022;9:816510Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model
/in Breast Cancer, Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2022-06-17 / Pharm Res 2022 Aug;39(8):1851-1866
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de